Narrative review of Alzheimer's disease without reported intervention or outcomes

Photo by Shawn Day / Unsplash

Frontiers in Medicine Published May 13, 2026 Medically reviewed May 13, 2026 Study authors: Tingting Li, Kanglin Guo, Yongxia Ma, Jianjun Zhao, Yanchun Cao, Run Zhang, Xiang Li, Jing Wei, Yufa… DOI ↗ By Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

Key Takeaway

Note that this narrative review lacks reported interventions, outcomes, or safety data for Alzheimer's disease.

This source is a narrative review focused on Alzheimer's disease. The document does not provide specific details regarding the study population, sample size, or clinical setting. Furthermore, the intervention or exposure of interest is not reported, nor is a comparator group identified within the text.

Primary outcomes and secondary outcomes are not reported in this document. The authors do not present pooled effect sizes, p-values, or confidence intervals because the necessary trial-level data are absent. Safety information, including adverse events, serious adverse events, discontinuations, and tolerability, is not reported.

The review acknowledges significant limitations by stating that follow-up duration and funding or conflicts of interest are not reported. Because the evidence is observational in nature and lacks specific quantitative data, causal language is avoided. The practice relevance of this narrative review is not reported, and the certainty of any potential conclusions is not defined.

Clinicians should interpret this document as a qualitative overview rather than a source of quantitative evidence for decision-making. No specific drug names, dosages, or disease-specific rates are provided to support clinical application.

Study Details

Study typeSystematic review

EvidenceLevel 1

PublishedMay 2026

View Original Abstract ↓

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by β-amyloid deposition, tau pathology, and sustained neuroinflammation. Increasing evidence indicates that dysregulated lipid metabolism is not merely a metabolic disturbance but a critical modulator of inflammatory responses driving AD pathogenesis. The brain, one of the most lipid-enriched organs, relies on tightly controlled lipid homeostasis to maintain neuronal function and synaptic integrity. Alterations in fatty acid composition, apolipoprotein E (ApoE) isoforms, lipoprotein lipase activity, and lipid-derived signaling mediators profoundly reshape microglial activation states and inflammatory cascades. Obesity, insulin resistance, and gut microbiota dysbiosis further exacerbate systemic and central lipid imbalance, amplifying neuroinflammatory signaling through cytokine networks and blood–brain barrier disruption. Notably, polyunsaturated fatty acids and lipid mediators exert dual immunomodulatory effects, influencing β-amyloid aggregation, oxidative stress, and microglial polarization. This review synthesizes recent advances in understanding how lipid metabolism modulates neuroinflammation and microglia–neuron crosstalk in AD, highlighting emerging therapeutic strategies targeting lipid–inflammation axes as promising avenues for disease modification.